

**GOVERNMENT OF INDIA
HEALTH AND FAMILY WELFARE
LOK SABHA**

UNSTARRED QUESTION NO:1823

ANSWERED ON:16.08.2013

QUALITY OF DRUGS

Adhi Sankar Shri ;Ahir Shri Hansraj Gangaram;Bhagora Shri Tarachand;Muttemwar Shri Vilas Baburao

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

- (a) whether the Government has taken note of fine imposed by a US court on Ranbaxy for selling drugs of inferior strength, purity or quality;
- (b) if so, the details thereof along with the reaction of the Government thereto; Original notice of the question received in Hindi.
- (c) the steps taken/proposed by the Government to ensure the quality, safety and efficacy of drugs being manufactured by Ranbaxy and other pharmaceutical companies in the country;
- (d) whether samples of certain drugs manufactured by Cipla have been found to be sub-standard by the drug inspectors in the country; and
- (e) if so, the facts in this regard and the action taken/proposed by the Government thereon?

Answer

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI GHULAM NABIAZAD)

(a) to (c): Yes. M/s Ranbaxy Inc., USA pleaded guilty in the US District Court of Maryland for manufacture and distribution of certain drugs not in conformity with the good manufacturing practices (GMP) regulation which is considered as adulterated drugs as per the laws of that country and agreed to pay a fine of USD500 million. Taking note of the matter, the Government has asked the Drugs Controller General (India) to review the GMP compliance of the manufacturing facilities of Ranbaxy in the country as well as to ascertain the quality, safety and efficacy of drugs manufactured for the domestic market at these facilities.

(d) and (e): The requisite information is being collected from the State Drugs Control Authorities and will be laid on the Table of the House.